United States Hemodialysis Market

United States Hemodialysis Market Size and Share:

The United States hemodialysis market size was valued at USD 22.4 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 34.7 Billion by 2033, exhibiting a CAGR of 5% from 2025-2033. The market is majorly driven by the increasing prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD), technological advancements in dialysis machines and home dialysis systems, rising adoption of home dialysis, growing awareness about kidney diseases, government initiatives and reimbursement policies, rapid innovations in remote monitoring and telemedicine, expanding dialysis center networks, and the increasing incidence of acute kidney injury (AKI).

The market is primarily driven by the rising prevalence of chronic kidney disease (CKD), particularly among the aging population and individuals with diabetes and hypertension. As the number of patients requiring dialysis increases, the demand for hemodialysis services and products is growing significantly. Technological advancements, such as improved dialysis machines, efficient dialyzers, and home dialysis solutions, offering better treatment outcomes and enhanced patient convenience, are also acting as key market drivers. Moreover, the growing adoption of nocturnal and short daily dialysis modalities among consumers is further fueling the market. Additionally, increased awareness of kidney disease and government initiatives to improve access to dialysis care are supporting market expansion. Apart from this, the shift towards patient-centric care, personalized treatment, and telemedicine also plays a significant role in shaping the future of the market.

The widespread availability of treatment throughout the country is essential in driving the expansion of the U.S. hemodialysis market due to the developed dialysis infrastructure and networks. As of June 30, 2024, 18 ESRD Networks oversee operations for 7,578 dialysis centers and 226 transplant centers across the United States and its territories, catering to a substantial patient population. Currently, there are 519,241 patients undergoing dialysis, 433,987 of whom are on hemodialysis in a center while 80,622 utilizing home dialysis options. Such benefits of an extensive and integrated network include accessibility of dialysis services to the patients in most cases even to the disadvantaged regions, as well as a variety of treatment services such as in-center dialysis, home and nursing home dialysis.

United States Hemodialysis Market Trends:

Increase in home dialysis adoption

The increasing preference for home-based treatment is a major factor bolstering the growth of hemodialysis in the United States. Enhanced dialysis systems and better monitoring facilities have contributed to this growing trend of patients opting for treatments at home rather than visiting a medical center. The latest report by the United States Renal Data System (USRDS) indicates that in the USA, 13.3% of new patients on dialysis prefer home dialysis. However, most patients currently commence kidney replacement therapy (KRT) through hemodialysis in an inpatient setting. Furthermore, the home dialysis model has an inbuilt approach to health care that involves less outside interference, thus creating attractive possibilities for lowering costs, customizing health care, and improving the quality of life of the patients.

Rising focus on supply chain resilience and dialysis accessibility

The increasing emphasis on strengthening supply chains for dialysis products is one of the major contributing factors that enhance the growth of the market. Recent interruptions, such as those caused by external shocks, especially natural calamities, have shown the vulnerability of the sector. For instance, on October 21, 2024, Baxter International stated that it was still working on restoring its peritoneal dialysis solutions supply to pre-interruption levels following supply chain issues that limited new patients. This step also involves reallocating more to children’s hospitals to ensure that at-risk patients receive the required treatment. Such measures indicate the increasing concerns in the sector about resolving supply imbalances in the provision of dialysis equipment to the market, and thus the improving stability and expansion of the market.

Rising incidences of acute kidney injury (AKI)

The increasing incidences of acute kidney injury (AKI) is contributing to the growing demand for hemodialysis treatments. As more patients are diagnosed with AKI during hospitalizations, the need for dialysis interventions has escalated. According to the USRDS 2023 Annual Data Report, the rate of hospitalizations with AKI was 62.5 per 1,000 person-years in 2021, showing a marginal rise from the previous year. Additionally, the proportion of hospitalizations involving AKI diagnosis increased from 15.5% in 2011 to 26.8% in 2021. AKI was most prevalent among patients hospitalized for sepsis (50.1%), non-sepsis infections (27.8%), and cancer (21%). This rising trend in AKI cases emphasizes the expanding need for dialysis services and is a significant factor driving the growth of the hemodialysis market.

United States Hemodialysis Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the United States hemodialysis market, along with forecasts at the country and regional levels from 2025-2033. The market has been categorized based on segment, modality, and end user.

Analysis by Segment:

• Hemodialysis Product
  • Machines
  • Dialyzers
  • Others
• Hemodialysis Services
  • In-center Services
  • Home Services
     

The hemodialysis products segment includes machines, dialyzers, and any other fundamental accessories employed during the process of hemodialysis treatment. Blood is pumped by a dialysis machine and waste is filtered by a dialyzer.

On the other hand, the hemodialysis service segment consists of in-center services, whereby a patient undergoes a dialysis treatment within a specialized clinic, and home services, which allow the patient to carry out the dialysis procedure, even at their home, with minimal monitoring, increasing comfort and flexibility.

Analysis by Modality:

• Conventional Hemodialysis
• Short Daily Hemodialysis
• Nocturnal Hemodialysis
   

Conventional hemodialysis is the conventional treatment of hemodialysis, performed three times per week in the hospital. Each session, which lasts on average 3-5 hours, involves using a machine to filter the patient’s blood in order to eliminate harmful compounds and excess liquids. For patients suffering from end-stage renal failure, conventional means of dialysis treatment such as this is still the most effective, as there are already set guidelines to this mode of treatment.

In the short daily hemodialysis modality, patients typically incur shorter dialysis sessions (generally 2-3 hours) but higher frequency usually 5-6 days a week. In short daily hemodialysis, there is enhanced clearance of fluid and toxins in contrast to the conventional treatment which is less strenuous on the heart and improves health. There is also improvement in the effectiveness of dialysis coupled with the comfort of increased flexibility for the patient.

Nocturnal hemodialysis is also another form of dialysis that takes place during the night whilst the patient is asleep. This is often done for a range of 6-8 hours. This improves toxin control as they are removed from the system over a more extended period and also improves fluid management. It is also gaining popularity among patients who want a dialysis treatment that does not offer any form of inconvenience.

Analysis by End User:

• Hospitals
• Independent Dialysis Centres
• Others
   

Hospitals are still the most significant external end-user in the hemodialysis market as they cater to a substantial number of patients suffering from kidney failure and offer all the possible services required in such cases. Such facilities have advanced treatment modalities and also do emergency dialysis procedures and have enough medical personnel and facilities to handle very difficult cases which are often located in a nephrology unit.

On the other hand, independent dialysis centres are dedicated centers which only offer hemodialysis services to patients suffering from chronic kidney disease (CKD). The approach taken in these centers is more straightforward where the patients choose their own appointments and attend treatments in more relaxed areas than when in hospital-based dialysis units. The services are available for both in-center dialysis and home patients therefore increasing the reach of hem dialysis services being provided.

Regional Analysis:

• Northeast
• Midwest
• South
• West
   

The Northeast region of the U.S. has a high concentration of healthcare facilities, including specialized dialysis centers, contributing to the robust demand for hemodialysis services. With a large aging population and increasing awareness of kidney disease, this region sees significant adoption of advanced dialysis treatments, particularly in major cities like New York and Boston.

On the other hand, the Midwest is characterized by a diverse healthcare landscape, with both urban and rural areas experiencing varying levels of dialysis care access. Larger cities such as Chicago and Detroit have advanced dialysis services, while rural regions face challenges in accessibility. The growing prevalence of chronic kidney disease in the region drives demand for both in-center and home dialysis treatments.

Moreover, the South has one of the highest incidences of chronic kidney disease in the U.S., particularly in states like Texas, Florida, and Georgia. With a large, aging population and disparities in healthcare access, this region shows strong growth in dialysis services, particularly in outpatient and independent dialysis centers, which cater to a broad range of patients seeking both in-center and home dialysis.

Apart from this, the West region, including states like California and Washington, is a leader in healthcare innovation, with widespread adoption of advanced dialysis technologies and home dialysis services. The region's focus on patient-centered care and telemedicine has supported the growth of both in-center and at-home dialysis options, with increasing efforts to improve access in more remote areas.

Competitive Landscape:

Key players in the market are driving growth through strategic collaborations, innovations in technology, and expanded service offerings. Major dialysis providers are enhancing patient care through advanced dialysis equipment, telemedicine integration, and personalized treatment plans. These companies are also investing in home dialysis solutions, addressing the growing demand for at-home care. Additionally, they focus on partnerships with healthcare providers to improve patient outcomes and reduce healthcare costs. The emphasis on automation, artificial intelligence for predictive analytics, and continuous treatment advancements further drives the market. Expanding their network of dialysis centers across the country strengthens their presence and improves patient accessibility.

The report provides a comprehensive analysis of the competitive landscape in the United States hemodialysis market with detailed profiles of all major companies.

Latest News and Developments:

• August 2024: Fresenius Medical Care (FME) received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its 5008X Hemodialysis System. This approval enables the company to introduce its advanced high-volume hemodiafiltration (Hv-HDF) dialysis therapy, which has already gained significant traction in Europe, to patients in the United States. The FDA clearance marks the beginning of clinical evaluations and user studies for the system in the U.S., with a full commercial launch planned for 2025.
• October 2024: U.S. Renal Care (USRC), one of the fastest-growing dialysis providers in the U.S., announced a multi-year commercial supply agreement with Akebia Therapeutics, a biopharmaceutical company dedicated to improving the lives of those affected by kidney disease. Under this agreement, USRC’s attending physicians will be able to prescribe Vafseo to dialysis patients, as deemed clinically appropriate, once the medication becomes available in January 2025. This collaboration aims to enhance treatment options for individuals undergoing dialysis and underscores the commitment of both companies to improving kidney care.
• August 2024: Baxter International Inc., a global medtech company, and Carlyle, a global investment firm, reached a definitive agreement for Carlyle to acquire Baxter's Kidney Care segment, which will be rebranded as Vantive, for USD3.8 Billion. As per the agreement, Baxter will receive around USD3.5 Bin cash, with an estimated net after-tax return of approximately USD3 Billion, subject to certain adjustments upon closing. This move follows Baxter's announcement in January 2023 to spin off its Kidney Care division into a standalone entity, as part of its broader strategic efforts to optimize future growth and deliver value to its stakeholders. This transaction will support the growth of the U.S. hemodialysis market by enabling Vantive, as a standalone kidney care company, to focus on specialized innovations and improvements in dialysis treatments, enhancing patient care and expanding access to advanced kidney care solutions across the country.

United States Hemodialysis Market Report Scope:

Key Benefits for Stakeholders:

• IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the United States hemodialysis market from 2019-2033.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the United States hemodialysis market.
• Porter's Five Forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the United States hemodialysis industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.